[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"article-CSN-051026064--":3,"related-articles-undefined-undefined-3b0c143a-1ddd-4edc-8eae-c9192ac88aac-true":15},{"id":4,"type":5,"title":6,"pubDate":7,"logoUrl":8,"anpFeedCategory":9,"organisationTitle":10,"thirdParty":11,"body":12,"orgId":13,"description":14},"CSN-051026064","PRESSRELEASE"," Ajinomoto Bio-Pharma Services Unveils Refreshed Global Brand, Showcasing its Strength in Specialization","2026-10-05T13:01:24.000+02:00","https:\u002F\u002Fwww.persberichten.nl\u002Fimg\u002Fpr-newswire.png","Economie","PR Newswire",true,"\u003Cp> - Reflects the depth of expertise and innovation Aji Bio-Pharma brings to customers navigating increasingly demanding development and manufacturing challenges\u003C\u002Fp>\u003Cp> TOKYO, Oct. 5, 2026 \u002FPRNewswire\u002F -- Ajinomoto Bio-Pharma Services (\"Aji Bio-Pharma\"), a global network of specialized contract development and manufacturing organizations (CDMOs) and enabling technologies, today unveiled a refreshed global brand including updated messaging and visual identity and a redeveloped global website that more clearly represents who the business is today and its commitment to supporting customers as they advance medicines that help improve the health of humankind.\u003C\u002Fp>\u003Cp> At a time when biopharma companies increasingly need depth of knowledge to navigate more demanding development and manufacturing challenges, Aji Bio-Pharma's strength lies in specialization. Across small molecules, oligonucleotides, peptides, gene therapy, proteins, and bioconjugates, its business brings dedicated focus to distinct areas of biopharma, paired with the scientific innovation to solve the challenges within them.\u003C\u002Fp>\u003Cp> Underpinning that specialization is Ajinomoto Group's history of more than a century of scientific innovation. That legacy continues to shape Aji Bio-Pharma today, including the development of proprietary technologies that create new possibilities in biopharma development and manufacturing. Together with shared commitments to quality, operational excellence, and sustainability, this enables Aji Bio-Pharma to provide the reliability and partnership customers depend on as they advance their programs.\u003C\u002Fp>\u003Cp> \"Our team has always been driven to find new and better ways to solve the specific development and manufacturing challenges our customers face,\" said Yasuyuki Otake, Corporate Executive, General Manager, Bio-Pharma Services Dept., Ajinomoto Co., Inc. \"Our new brand puts that strength at the center. It reflects the ingenuity of our teams around the world and our commitment to helping customers unlock innovation and unleash the potential of their science for the patients they serve.\"\u003C\u002Fp>\u003Cp> The new brand launches today on Aji Bio-Pharma's website, social media channels, and through updated global marketing materials at upcoming conferences, with additional assets transitioning to the new identity over the coming months.\u003C\u002Fp>\u003Cp> About Ajinomoto Bio-Pharma ServicesAjinomoto Bio-Pharma Services is a global network of specialized contract development and manufacturing organizations (CDMOs) and enabling technologies with expertise across small molecules, oligonucleotides, peptides, gene therapy, proteins, and bioconjugates. With businesses and manufacturing sites in Belgium, India, Japan, and the U.S., we combine deep modality knowledge with Ajinomoto Group's century-long legacy of scientific innovation and share a commitment to quality, operational excellence, and sustainability to help biopharma partners advance complex and novel medicines and help improve the health of humankind. Learn more at \u003Ca target=\"_blank\" href=\"https:\u002F\u002Fedge.prnewswire.com\u002Fc\u002Flink\u002F?t=0&l=en&o=4787945-1&h=3976282309&u=https%3A%2F%2Fwww.ajibio-pharma.com%2F&a=www.AjiBio-Pharma.com\">www.AjiBio-Pharma.com.\u003C\u002Fa>\u003C\u002Fp>\u003Cp> Media InquiriesFor media inquiries, please contact: \u003Ca target=\"_blank\" href=\"https:\u002F\u002Fedge.prnewswire.com\u002Fc\u002Flink\u002F?t=0&l=en&o=4787945-1&h=254092543&u=https%3A%2F%2Fwww.ajibio-pharma.com%2Fcontact-us%2Foverview%2F&a=HERE\">HERE\u003C\u002Fa>\u003C\u002Fp>\u003Cp> View original content to download multimedia:https:\u002F\u002Fwww.prnewswire.co.uk\u002Fnews-releases\u002Fajinomoto-bio-pharma-services-unveils-refreshed-global-brand-showcasing-its-strength-in-specialization-302898326.html\u003C\u002Fp>","3b0c143a-1ddd-4edc-8eae-c9192ac88aac","- Reflects the depth of expertise and innovation Aji Bio-Pharma brings to customers navigating increasingly demanding development and manufacturing challenges T",[16,21,26,31,32,37,42,47,52,56],{"id":17,"title":18,"pubDate":19,"logoUrl":8,"thirdParty":11,"orgId":13,"description":20},"CSN-051026082"," Habitat for Humanity's new global research report finds three in four people are cutting back on essentials to afford housing","2026-10-05T14:01:27.000+02:00","ATLANTA, Oct. 5, 2026 \u002FPRNewswire\u002F -- Housing costs are forcing millions of people around the world into difficult trade-offs, coming at the expense of food, he",{"id":22,"title":23,"pubDate":24,"logoUrl":8,"thirdParty":11,"orgId":13,"description":25},"CSN-051026067"," SignSplit Secures $400 Million Strategic Seed Round at $1 Billion Valuation","2026-10-05T13:05:24.000+02:00","The technology startup enables people and institutions to protect, license and receive compensation for their data, work and likeness — connecting them with the",{"id":27,"title":28,"pubDate":29,"logoUrl":8,"thirdParty":11,"orgId":13,"description":30},"CSN-051026065"," Quantinuum and The University of Western Australia Partner to Advance Australia's Quantum Capability","2026-10-05T13:01:25.000+02:00","- Quantinuum and The University of Western Australia (UWA) sign MOU to help prepare Australia's workforce and innovation ecosystem for the hybrid quantum-AI-HPC",{"id":4,"title":6,"pubDate":7,"logoUrl":8,"thirdParty":11,"orgId":13,"description":14},{"id":33,"title":34,"pubDate":35,"logoUrl":8,"thirdParty":11,"orgId":13,"description":36},"CSN-051026049"," METLEN: New gallium agreement with major Japanese chemical company","2026-10-05T11:17:24.000+02:00","METLEN attracts global commercial interest in European gallium New agreement with major Japanese chemical company highlights strong global market demand ATHENS,",{"id":38,"title":39,"pubDate":40,"logoUrl":8,"thirdParty":11,"orgId":13,"description":41},"CSN-051026038"," MediaTek and Airoha Accelerate Global Network Infrastructure Upgrades for the AI Era","2026-10-05T09:31:25.000+02:00","Showcasing Wi-Fi, 5G CPE and PON Platforms at Network X 2026—Assisting Global Operators in Upgrading Infrastructure with Higher Bandwidth, Ultra-Low Latency and",{"id":43,"title":44,"pubDate":45,"logoUrl":8,"thirdParty":11,"orgId":13,"description":46},"CSN-051026030"," Sovereign Wealth Fund Institute announces first I20 Summit alongside G20 Leaders' Summit, targets US$5tn capital deployment into US","2026-10-05T09:01:24.000+02:00","- Five-day event set for Miami (11–15 December 2026) alongside the G20 Leaders' Summit at Trump National Doral. - Convenes global sovereign, pension, and instit",{"id":48,"title":49,"pubDate":50,"logoUrl":8,"thirdParty":11,"orgId":13,"description":51},"CSN-051026025"," TCL LINKHUB HH516 Becomes the World's First Dedicated 5G FWA CPE to Achieve prplWare Certification","2026-10-05T08:01:25.000+02:00","PARIS, Oct. 5, 2026 \u002FPRNewswire\u002F -- TCL, a global leader in consumer electronics, today announced that the TCL LINKHUB HH516 has become the world's first purpos",{"id":53,"title":54,"pubDate":50,"logoUrl":8,"thirdParty":11,"orgId":13,"description":55},"CSN-051026024"," 8th RD20 Conference to Be Held in South Africa, Its First in Africa","PRETORIA, South Africa and TOKYO, Oct. 5, 2026 \u002FPRNewswire\u002F -- The 8th RD20 Conference will be held on October 19-23, 2026, in Pretoria, South Africa, hosted by",{"id":57,"title":58,"pubDate":59,"logoUrl":8,"thirdParty":11,"orgId":13,"description":60},"CSN-051026016"," AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)","2026-10-05T06:31:25.000+02:00","The only known investigational therapy for SBMA in Phase 3 development worldwide - AJ201 (rosolutamide) is an investigational oral small molecule designed to ad"]